{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:30:41Z","timestamp":1791729041511,"version":"4.3.4"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":1575,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1093\/annonc\/mdv297","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T05:22:27Z","timestamp":1440652947000},"page":"v126-v132","source":"Crossref","is-referenced-by-count":309,"special_numbering":"S5","title":["Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"26","author":[{"given":"R.","family":"Dummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Lindenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv297_bb0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/annonc\/mdr128","article-title":"Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989","volume":"23","author":"Hollestein","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjd.12923","article-title":"Melanoma prognosis in Europe: far from equal","volume":"171","author":"Forsea","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdv297_bb0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.2010.28.7078","article-title":"Reduced melanoma after regular sunscreen use: randomized trial follow-up","volume":"29","author":"Green","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0025","first-page":"w13320","article-title":"Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma","volume":"141","author":"Dummer","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"10.1093\/annonc\/mdv297_bb0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2133.2006.07396.x","article-title":"Micro-melanoma detection: a clinical study on 206 consecutive cases of pigmented skin lesions with a diameter < or = 3 mm","volume":"155","author":"Bono","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdv297_bb0035","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1001\/archderm.134.1.103-a","article-title":"The \u2018ugly duckling\u2019 sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening","volume":"134","author":"Grob","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdv297_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(02)00679-4","article-title":"Diagnostic accuracy of dermoscopy","volume":"3","author":"Kittler","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0045","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0050","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1755-148X.2011.00880.x","article-title":"The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin","volume":"24","author":"Whiteman","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdv297_bb0055","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1093\/annonc\/mdv297_bb0060","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.ejca.2012.02.049","article-title":"Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations","volume":"48","author":"Schoenewolf","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv297_bb0065","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1084\/jem.20041896","article-title":"VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis","volume":"201","author":"Hirakawa","year":"2005","journal-title":"J Exp Med"},{"key":"10.1093\/annonc\/mdv297_bb0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(05)70937-5","article-title":"Cutaneous melanoma","volume":"365","author":"Thompson","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv297_bb0075","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","article-title":"Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma","volume":"31","author":"Han","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0080","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJMoa060992","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0085","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ejca.2011.09.028","article-title":"Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991","volume":"48","author":"Eggermont","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv297_bb0090","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","article-title":"High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190","volume":"18","author":"Kirkwood","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0095","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis","volume":"102","author":"Mocellin","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv297_bb0100","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv297_bb0105","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.2011.41.3799","article-title":"Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma","volume":"30","author":"Eggermont","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv297_bb0115","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ejca.2003.07.004","article-title":"Final results of the EORTC 18871\/DKG 80\u20131 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis","volume":"40","author":"Kleeberg","year":"2004","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv297_bb0120","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0125","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0130","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1200\/JCO.2011.41.1660","article-title":"Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition","volume":"30","author":"Zimmer","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0135","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1046\/j.1365-2133.2002.04750.x","article-title":"A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays","volume":"146","author":"Farshad","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1093\/annonc\/mdv297_bb0140","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1470-2045(12)70138-9","article-title":"Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial","volume":"13","author":"Burmeister","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0145","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PPO.0b013e31824b241a","article-title":"Role of radiation therapy in cutaneous melanoma","volume":"18","author":"Hong","year":"2012","journal-title":"Cancer J"},{"key":"10.1093\/annonc\/mdv297_bb0150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jso.23512","article-title":"Treatment of metastatic melanoma with electrochemotherapy","volume":"109","author":"Campana","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(14)70007-5","article-title":"Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials","volume":"15","author":"Flaherty","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0165","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0170","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0175","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0180","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0185","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0190","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0195","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0200","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0205","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0210","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0215","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv297_bb0220","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4-treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv297_bb0225","doi-asserted-by":"crossref","first-page":"05","DOI":"10.1186\/1479-5876-13-S1-O5","article-title":"A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma","volume":"13","author":"Dummer","year":"2015","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdv297_bb0230","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S1470-2045(13)70237-7","article-title":"Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study","volume":"14","author":"Robert","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0240","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0245","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv297_bb0250","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/archderm.142.4.433","article-title":"Multiple primary melanoma: two-year results from a population-based study","volume":"142","author":"Titus-Ernstoff","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1093\/annonc\/mdv297_bb0255","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1200\/JCO.2010.34.2956","article-title":"Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma","volume":"29","author":"Turner","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0260","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1200\/JCO.2008.20.1822","article-title":"Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment","volume":"27","author":"Bastiaannet","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv297_bb0265","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.soc.2005.12.005","article-title":"The conundrum of follow-up: should it be abandoned?","volume":"15","author":"Nieweg","year":"2006","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1093\/annonc\/mdv297_bb0270","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000095034","article-title":"Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein","volume":"213","author":"Beyeler","year":"2006","journal-title":"Dermatology"},{"key":"10.1093\/annonc\/mdv297_bb0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419471809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419471809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/suppl_5\/v126\/6676108\/mdv297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T01:13:06Z","timestamp":1589245986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419471809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":54,"alternative-id":["S0923753419471809"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv297","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]}}}